Published
{
"ticker": "MDT",
"cik": "0001613103",
"company": "Medtronic plc",
"business_type": "industrial",
"schema_template": "standard (industrial/medical device manufacturer): net sales, cost of products sold, operating profit, net income, EPS and share counts; cash, debt, assets and equity; operating cash flow, capital expenditures and free cash flow",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual dollars (not millions); share counts are actual shares; per-share figures are in dollars per ordinary share",
"units_notes_seen": {
"FY2026 10-K consolidated statements of income": "(in millions, except per share data)",
"FY2026 10-K consolidated statements of comprehensive income": "(in millions)",
"FY2026 10-K consolidated balance sheets": "(in millions, except share amounts)",
"FY2026 10-K consolidated statements of equity": "(in millions, except per share data)",
"FY2026 10-K consolidated statements of cash flows": "(in millions)",
"Q3 FY2026 10-Q consolidated statements of income": "(in millions, except per share data)",
"Q3 FY2026 10-Q consolidated balance sheets": "(in millions)",
"Q3 FY2026 10-Q consolidated statements of equity": "(in millions)",
"Q3 FY2026 10-Q consolidated statements of cash flows": "(in millions)",
"Q4 FY2026 earnings release consolidated statements of income": "(in millions, except per share data)",
"Q4 FY2026 earnings release consolidated statements of cash flows": "(in millions)"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "None. Medtronic plc reports in U.S. dollars, so no currency conversion was applied."
},
"annual": [
{
"fiscal_year": 2026,
"label": "FY2026",
"period_start": "2025-04-26",
"period_end": "2026-04-24",
"period_type": "fiscal year",
"source_accession": "0001628280-26-044354",
"income_statement": {
"net_sales": 36364000000,
"cost_of_products_sold": 12721000000,
"research_and_development_expense": 2873000000,
"selling_general_and_administrative_expense": 11784000000,
"amortization_of_intangible_assets": 1772000000,
"restructuring_charges_net": 249000000,
"certain_litigation_charges_net": 113000000,
"other_operating_expense_income_net": 386000000,
"operating_profit": 6467000000,
"other_non_operating_expense_income_net": -384000000,
"interest_expense_net": 715000000,
"income_before_income_taxes": 6136000000,
"income_tax_provision": 1299000000,
"net_income": 4837000000,
"net_income_attributable_to_noncontrolling_interests": 37000000,
"net_income_attributable_to_medtronic": 4801000000,
"basic_eps": 3.75,
"diluted_eps": 3.73,
"diluted_weighted_average_shares": 1288100000,
"gross_profit_derived": 23643000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 1949000000,
"investments": 7271000000,
"accounts_receivable_net": 6643000000,
"inventories": 5951000000,
"other_current_assets": 2972000000,
"total_current_assets": 24787000000,
"property_plant_and_equipment_net": 7417000000,
"goodwill": 42587000000,
"other_intangible_assets_net": 10146000000,
"total_assets": 93028000000,
"current_debt_obligations": 1788000000,
"accounts_payable": 2644000000,
"total_current_liabilities": 11658000000,
"long_term_debt": 26173000000,
"total_liabilities": 42956000000,
"retained_earnings": 32638000000,
"total_shareholders_equity": 49463000000,
"noncontrolling_interests": 609000000,
"total_equity": 50072000000,
"total_debt": 27961000000,
"ordinary_shares_issued_and_outstanding": 1280177293
},
"cash_flow": {
"depreciation_and_amortization": 2958000000,
"stock_based_compensation": 457000000,
"net_cash_provided_by_operating_activities": 7330000000,
"acquisitions_net_of_cash_acquired": -406000000,
"additions_to_property_plant_and_equipment": -1904000000,
"net_cash_used_in_investing_activities": -2934000000,
"issuance_of_long_term_debt": 1747000000,
"payments_on_long_term_debt": -2930000000,
"dividends_to_shareholders": -3639000000,
"issuance_of_ordinary_shares": 516000000,
"repurchase_of_ordinary_shares": -1035000000,
"net_cash_used_in_financing_activities": -4751000000,
"cash_and_cash_equivalents_at_end_of_period": 1949000000,
"free_cash_flow": 5426000000
}
},
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2024-04-27",
"period_end": "2025-04-25",
"period_type": "fiscal year",
"source_accession": "0001628280-26-044354",
"income_statement": {
"net_sales": 33537000000,
"cost_of_products_sold": 11632000000,
"research_and_development_expense": 2732000000,
"selling_general_and_administrative_expense": 10849000000,
"amortization_of_intangible_assets": 1807000000,
"restructuring_charges_net": 267000000,
"certain_litigation_charges_net": 317000000,
"other_operating_expense_income_net": -23000000,
"operating_profit": 5955000000,
"other_non_operating_expense_income_net": -402000000,
"interest_expense_net": 729000000,
"income_before_income_taxes": 5628000000,
"income_tax_provision": 936000000,
"net_income": 4691000000,
"net_income_attributable_to_noncontrolling_interests": 29000000,
"net_income_attributable_to_medtronic": 4662000000,
"basic_eps": 3.63,
"diluted_eps": 3.61,
"diluted_weighted_average_shares": 1289900000,
"gross_profit_derived": 21905000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 2218000000,
"investments": 6747000000,
"accounts_receivable_net": 6515000000,
"inventories": 5476000000,
"other_current_assets": 2858000000,
"total_current_assets": 23814000000,
"property_plant_and_equipment_net": 6837000000,
"goodwill": 41737000000,
"other_intangible_assets_net": 11667000000,
"total_assets": 91680000000,
"current_debt_obligations": 2874000000,
"accounts_payable": 2449000000,
"total_current_liabilities": 12879000000,
"long_term_debt": 25642000000,
"total_liabilities": 43424000000,
"retained_earnings": 31476000000,
"total_shareholders_equity": 48024000000,
"noncontrolling_interests": 232000000,
"total_equity": 48256000000,
"total_debt": 28516000000,
"ordinary_shares_issued_and_outstanding": 1281934628
},
"cash_flow": {
"depreciation_and_amortization": 2861000000,
"stock_based_compensation": 429000000,
"net_cash_provided_by_operating_activities": 7044000000,
"acquisitions_net_of_cash_acquired": -98000000,
"additions_to_property_plant_and_equipment": -1859000000,
"net_cash_used_in_investing_activities": -1937000000,
"issuance_of_long_term_debt": 3209000000,
"payments_on_long_term_debt": 0,
"dividends_to_shareholders": -3589000000,
"issuance_of_ordinary_shares": 508000000,
"repurchase_of_ordinary_shares": -3235000000,
"net_cash_used_in_financing_activities": -4361000000,
"cash_and_cash_equivalents_at_end_of_period": 2218000000,
"free_cash_flow": 5185000000
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2023-04-29",
"period_end": "2024-04-26",
"period_type": "fiscal year",
"source_accession": "0001628280-26-044354",
"income_statement": {
"net_sales": 32364000000,
"cost_of_products_sold": 11216000000,
"research_and_development_expense": 2735000000,
"selling_general_and_administrative_expense": 10736000000,
"amortization_of_intangible_assets": 1693000000,
"restructuring_charges_net": 226000000,
"certain_litigation_charges_net": 149000000,
"other_operating_expense_income_net": 464000000,
"operating_profit": 5144000000,
"other_non_operating_expense_income_net": -412000000,
"interest_expense_net": 719000000,
"income_before_income_taxes": 4837000000,
"income_tax_provision": 1133000000,
"net_income": 3705000000,
"net_income_attributable_to_noncontrolling_interests": 28000000,
"net_income_attributable_to_medtronic": 3676000000,
"basic_eps": 2.77,
"diluted_eps": 2.76,
"diluted_weighted_average_shares": 1330200000,
"gross_profit_derived": 21148000000
},
"cash_flow": {
"depreciation_and_amortization": 2647000000,
"stock_based_compensation": 393000000,
"net_cash_provided_by_operating_activities": 6787000000,
"acquisitions_net_of_cash_acquired": -211000000,
"additions_to_property_plant_and_equipment": -1587000000,
"net_cash_used_in_investing_activities": -2366000000,
"issuance_of_long_term_debt": 0,
"payments_on_long_term_debt": 0,
"dividends_to_shareholders": -3666000000,
"issuance_of_ordinary_shares": 284000000,
"repurchase_of_ordinary_shares": -2138000000,
"net_cash_used_in_financing_activities": -4450000000,
"cash_and_cash_equivalents_at_end_of_period": 1284000000,
"free_cash_flow": 5200000000
}
}
],
"quarterly": [
{
"label": "Q4 FY2026",
"fiscal_year": 2026,
"fiscal_quarter": 4,
"period_start": "2026-01-24",
"period_end": "2026-04-24",
"period_type": "three months",
"source_accession": "0001628280-26-040034",
"income_statement": {
"net_sales": 9807000000,
"cost_of_products_sold": 3398000000,
"research_and_development_expense": 671000000,
"selling_general_and_administrative_expense": 3056000000,
"amortization_of_intangible_assets": 409000000,
"restructuring_charges_net": 118000000,
"certain_litigation_charges_net": 23000000,
"other_operating_expense_income_net": 260000000,
"operating_profit": 1873000000,
"other_non_operating_expense_income_net": -138000000,
"interest_expense_net": 176000000,
"income_before_income_taxes": 1834000000,
"income_tax_provision": 575000000,
"net_income": 1259000000,
"net_income_attributable_to_noncontrolling_interests": 16000000,
"net_income_attributable_to_medtronic": 1243000000,
"basic_eps": 0.97,
"diluted_eps": 0.96,
"diluted_weighted_average_shares": 1288200000,
"gross_profit_derived": 6409000000
}
},
{
"label": "Q3 FY2026",
"fiscal_year": 2026,
"fiscal_quarter": 3,
"period_start": "2025-10-25",
"period_end": "2026-01-23",
"period_type": "three months",
"source_accession": "0001628280-26-011107",
"income_statement": {
"net_sales": 9017000000,
"cost_of_products_sold": 3261000000,
"research_and_development_expense": 722000000,
"selling_general_and_administrative_expense": 2956000000,
"amortization_of_intangible_assets": 441000000,
"restructuring_charges_net": 77000000,
"certain_litigation_charges_net": 62000000,
"other_operating_expense_income_net": 35000000,
"operating_profit": 1464000000,
"other_non_operating_expense_income_net": -121000000,
"interest_expense_net": 181000000,
"income_before_income_taxes": 1404000000,
"income_tax_provision": 254000000,
"net_income": 1150000000,
"net_income_attributable_to_noncontrolling_interests": 6000000,
"net_income_attributable_to_medtronic": 1143000000,
"basic_eps": 0.89,
"diluted_eps": 0.89,
"diluted_weighted_average_shares": 1289500000,
"gross_profit_derived": 5756000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 1147000000,
"investments": 7236000000,
"accounts_receivable_net": 6359000000,
"inventories": 6309000000,
"other_current_assets": 3020000000,
"total_current_assets": 24071000000,
"property_plant_and_equipment_net": 7179000000,
"goodwill": 41892000000,
"other_intangible_assets_net": 10335000000,
"total_assets": 91485000000,
"current_debt_obligations": 191000000,
"accounts_payable": 2569000000,
"total_current_liabilities": 9495000000,
"long_term_debt": 27880000000,
"total_liabilities": 42289000000,
"retained_earnings": 32303000000,
"total_shareholders_equity": 48985000000,
"noncontrolling_interests": 211000000,
"total_equity": 49196000000,
"total_debt": 28071000000,
"ordinary_shares_issued_and_outstanding": 1283366516
}
},
{
"label": "Q4 FY2025",
"fiscal_year": 2025,
"fiscal_quarter": 4,
"period_start": "2025-01-25",
"period_end": "2025-04-25",
"period_type": "three months",
"source_accession": "0001628280-26-040034",
"income_statement": {
"net_sales": 8927000000,
"cost_of_products_sold": 3147000000,
"research_and_development_expense": 684000000,
"selling_general_and_administrative_expense": 2721000000,
"amortization_of_intangible_assets": 564000000,
"restructuring_charges_net": 147000000,
"certain_litigation_charges_net": 214000000,
"other_operating_expense_income_net": 15000000,
"operating_profit": 1436000000,
"other_non_operating_expense_income_net": 1000000,
"interest_expense_net": 174000000,
"income_before_income_taxes": 1261000000,
"income_tax_provision": 199000000,
"net_income": 1061000000,
"net_income_attributable_to_noncontrolling_interests": 5000000,
"net_income_attributable_to_medtronic": 1057000000,
"basic_eps": 0.82,
"diluted_eps": 0.82,
"diluted_weighted_average_shares": 1287700000,
"gross_profit_derived": 5780000000
}
},
{
"label": "Q3 FY2025",
"fiscal_year": 2025,
"fiscal_quarter": 3,
"period_start": "2024-10-26",
"period_end": "2025-01-24",
"period_type": "three months",
"source_accession": "0001628280-26-011107",
"income_statement": {
"net_sales": 8292000000,
"cost_of_products_sold": 2779000000,
"research_and_development_expense": 675000000,
"selling_general_and_administrative_expense": 2717000000,
"amortization_of_intangible_assets": 416000000,
"restructuring_charges_net": 43000000,
"certain_litigation_charges_net": 22000000,
"other_operating_expense_income_net": -5000000,
"operating_profit": 1646000000,
"other_non_operating_expense_income_net": -72000000,
"interest_expense_net": 179000000,
"income_before_income_taxes": 1540000000,
"income_tax_provision": 237000000,
"net_income": 1303000000,
"net_income_attributable_to_noncontrolling_interests": 9000000,
"net_income_attributable_to_medtronic": 1294000000,
"basic_eps": 1.01,
"diluted_eps": 1.01,
"diluted_weighted_average_shares": 1286200000,
"gross_profit_derived": 5513000000
}
}
],
"year_to_date": {
"label": "First nine months of FY2026",
"period_start": "2025-04-26",
"period_end": "2026-01-23",
"period_type": "nine months",
"source_accession": "0001628280-26-011107",
"income_statement": {
"net_sales": 26557000000,
"cost_of_products_sold": 9323000000,
"gross_profit_derived": 17234000000,
"research_and_development_expense": 2202000000,
"selling_general_and_administrative_expense": 8727000000,
"amortization_of_intangible_assets": 1364000000,
"restructuring_charges_net": 131000000,
"certain_litigation_charges_net": 89000000,
"other_operating_expense_income_net": 126000000,
"operating_profit": 4594000000,
"other_non_operating_expense_income_net": -247000000,
"interest_expense_net": 539000000,
"income_before_income_taxes": 4302000000,
"income_tax_provision": 724000000,
"net_income": 3578000000,
"net_income_attributable_to_noncontrolling_interests": 21000000,
"net_income_attributable_to_medtronic": 3557000000,
"basic_eps": 2.77,
"diluted_eps": 2.76,
"diluted_weighted_average_shares": 1288200000
},
"cash_flow": {
"depreciation_and_amortization": 2242000000,
"stock_based_compensation": 362000000,
"net_cash_provided_by_operating_activities": 4757000000,
"additions_to_property_plant_and_equipment": -1416000000,
"free_cash_flow": 3341000000,
"acquisitions_net_of_cash_acquired": 0,
"net_cash_used_in_investing_activities": -2017000000,
"issuance_of_long_term_debt": 1747000000,
"payments_on_long_term_debt": -2930000000,
"dividends_to_shareholders": -2731000000,
"issuance_of_ordinary_shares": 419000000,
"repurchase_of_ordinary_shares": -600000000,
"net_cash_used_in_financing_activities": -3863000000,
"cash_and_cash_equivalents_at_end_of_period": 1147000000
}
},
"notes": [
"Medtronic uses a 52/53-week fiscal year ending on the last Friday in April. Fiscal 2026 ended April 24, 2026, fiscal 2025 ended April 25, 2025 and fiscal 2024 ended April 26, 2024. Each period's start date shown here is the day after the preceding period closed, as those closing dates are printed in the statements of equity.",
"Annual figures for fiscal 2026, 2025 and 2024 are taken from the consolidated statements of income and cash flows in the fiscal 2026 Form 10-K (accession 0001628280-26-044354), which presents three years of income and cash flow but only two balance sheet dates. Fiscal 2024 therefore carries no balance sheet here: that balance sheet is not in this filing.",
"Third-quarter figures for fiscal 2026 and fiscal 2025 (the three months ended January 23, 2026 and January 24, 2025), and the balance sheet at January 23, 2026, are taken from the Form 10-Q for the third quarter of fiscal 2026 (accession 0001628280-26-011107).",
"Fourth-quarter figures for fiscal 2026 and fiscal 2025 (the three months ended April 24, 2026 and April 25, 2025) are not printed as separate columns in the 10-K. They are taken from the consolidated statements of income in the fourth-quarter and full-year fiscal 2026 earnings release, furnished as Exhibit 99.1 to the Form 8-K dated June 3, 2026 (accession 0001628280-26-040034). Those statements are unaudited and stated in millions, and their fiscal-year columns agree line for line with the audited 10-K. The fourth quarter of fiscal 2026 is the balance of the year after the first nine months: $9,807 million of net sales against $36,364 million for the full fiscal year and $26,557 million for the nine months ended January 23, 2026.",
"The quarters shown here are the third and fourth quarters of fiscal 2026 and fiscal 2025. Those are the three-month periods the fiscal 2026 Form 10-K and the third-quarter fiscal 2026 Form 10-Q account for: the 10-Q presents each third quarter on its face, and each fourth quarter is the 10-K's audited fiscal year less the nine months the 10-Q reports. The first and second quarters of fiscal 2026 are not shown. Neither the 10-K nor the 10-Q presents them, and Medtronic reported those two quarters only in the earnings releases furnished with its Forms 8-K of August 19, 2025 (accession 0001613103-25-000141) and November 18, 2025 (accession 0001628280-25-052771).",
"The quarterly entries carry no cash flow statement. The 10-Q presents cash flows for the nine months only and the earnings release presents them for the full fiscal year only, so neither filing puts a three-month cash flow column on its face and none is reported here.",
"Medtronic's income statement does not print a gross profit subtotal, so gross_profit_derived is net sales less cost of products sold. Cost of products sold excludes amortization of intangible assets, which the company reports on its own line; this is the same basis on which Medtronic states its gross margin percentage (65.4% for the fourth quarter of fiscal 2026).",
"Two expense lines are stored exactly as the filings print them, so a negative amount means net income rather than net expense: other_operating_expense_income_net and other_non_operating_expense_income_net. Cash outflows in the cash flow statements are likewise stored as negative amounts. net_income_attributable_to_noncontrolling_interests does not follow that convention: the income statement prints it in parentheses, but it is stored here as a positive amount, because it is income earned by the noncontrolling interests in Medtronic's consolidated subsidiaries. It is deducted from consolidated net income to arrive at net income attributable to Medtronic.",
"net_income is the consolidated figure including noncontrolling interests; net_income_attributable_to_medtronic is the parent's share and is the figure earnings per share is struck on.",
"total_debt is the sum of the two debt captions on the balance sheet, current debt obligations plus long-term debt. It does not include lease liabilities.",
"free_cash_flow is operating cash flow less additions to property, plant and equipment, which is the company's own definition. The results are $5,426 million for fiscal 2026, $5,185 million for fiscal 2025 and $5,200 million for fiscal 2024, the same figures Medtronic reports in its fiscal 2026 earnings release.",
"On March 9, 2026 MiniMed Group, Inc., which holds Medtronic's Diabetes business, completed an initial public offering. Medtronic retained a controlling financial interest, so MiniMed's results remain consolidated in every period shown. The $538 million of offering proceeds appears in fiscal 2026 financing activities, and noncontrolling interests on the balance sheet rose from $232 million at April 25, 2025 to $609 million at April 24, 2026.",
"The year_to_date block is the nine months ended January 23, 2026 as presented in the third-quarter 10-Q. No trailing-twelve-month block is reported: with fiscal 2026 complete, the trailing twelve months to April 24, 2026 is the fiscal 2026 year already shown in full.",
"No restatement was found. The fiscal 2026 and fiscal 2025 columns of the June 3, 2026 earnings release match the 10-K line for line, and the April 25, 2025 balance sheet is identical in the 10-K and the 10-Q."
],
"uncertainties": [
"The two fourth-quarter periods come from an earnings release rather than a periodic report. Those statements are unaudited, are rounded to the nearest million, and the release itself cautions that the quarterly amounts may not sum exactly to the fiscal-year totals.",
"Gross profit and total debt are not lines Medtronic prints; both are computed here from printed lines, as described in the notes.",
"Fiscal 2024 is reported without a balance sheet, and the three-month periods without cash flow statements, because those columns do not appear in the filings this record is drawn from.",
"The quarter that began after fiscal 2026 closed is outside this record. Medtronic announced first-quarter fiscal 2027 results on September 1, 2026, and no Form 10-Q for that quarter had been filed when this record was prepared."
],
"headline": {
"period": "FY2026",
"period_end_words": "April 24, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 36364000000,
"text": "$36.36 billion",
"exact": "$36,364,000,000",
"compact": "$36.36B",
"abs": "$36.36 billion",
"prior_value": 33537000000,
"prior": "$33.54 billion",
"priorabs": "$33.54 billion",
"yoy": "up 8.4%",
"source": {
"array": "annual",
"field": "income_statement.net_sales",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-04-24",
"period_start": "2025-04-26",
"span_days": 363,
"source_accession": "0001628280-26-044354",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-04-25",
"prior_period_start": "2024-04-27",
"prior_span_days": 363,
"prior_source_accession": "0001628280-26-044354",
"gap_days": 364
}
},
{
"label": "Net income",
"format": "usd",
"value": 4801000000,
"text": "$4.80 billion",
"exact": "$4,801,000,000",
"compact": "$4.80B",
"abs": "$4.80 billion",
"prior_value": 4662000000,
"prior": "$4.66 billion",
"priorabs": "$4.66 billion",
"yoy": "up 3.0%",
"source": {
"array": "annual",
"field": "income_statement.net_income_attributable_to_medtronic",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-04-24",
"period_start": "2025-04-26",
"span_days": 363,
"source_accession": "0001628280-26-044354",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-04-25",
"prior_period_start": "2024-04-27",
"prior_span_days": 363,
"prior_source_accession": "0001628280-26-044354",
"gap_days": 364
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 3.73,
"text": "$3.73",
"exact": "$3.73",
"compact": "$3.73",
"abs": "$3.73",
"prior_value": 3.61,
"prior": "$3.61",
"priorabs": "$3.61",
"yoy": "up 3.3%",
"source": {
"array": "annual",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-04-24",
"period_start": "2025-04-26",
"span_days": 363,
"source_accession": "0001628280-26-044354",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-04-25",
"prior_period_start": "2024-04-27",
"prior_span_days": 363,
"prior_source_accession": "0001628280-26-044354",
"gap_days": 364
}
},
{
"label": "Operating profit",
"format": "usd",
"value": 6467000000,
"text": "$6.47 billion",
"exact": "$6,467,000,000",
"compact": "$6.47B",
"abs": "$6.47 billion",
"prior_value": 5955000000,
"prior": "$5.96 billion",
"priorabs": "$5.96 billion",
"yoy": "up 8.6%",
"source": {
"array": "annual",
"field": "income_statement.operating_profit",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-04-24",
"period_start": "2025-04-26",
"span_days": 363,
"source_accession": "0001628280-26-044354",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-04-25",
"prior_period_start": "2024-04-27",
"prior_span_days": 363,
"prior_source_accession": "0001628280-26-044354",
"gap_days": 364
}
},
{
"label": "Free cash flow",
"format": "usd",
"value": 5426000000,
"text": "$5.43 billion",
"exact": "$5,426,000,000",
"compact": "$5.43B",
"abs": "$5.43 billion",
"prior_value": 5185000000,
"prior": "$5.18 billion",
"priorabs": "$5.18 billion",
"yoy": "up 4.6%",
"source": {
"array": "annual",
"field": "cash_flow.free_cash_flow",
"index": 0,
"period_label": "FY2026",
"period_end": "2026-04-24",
"period_start": "2025-04-26",
"span_days": 363,
"source_accession": "0001628280-26-044354",
"prior_index": 1,
"prior_period_label": "FY2025",
"prior_period_end": "2025-04-25",
"prior_period_start": "2024-04-27",
"prior_span_days": 363,
"prior_source_accession": "0001628280-26-044354",
"gap_days": 364
}
}
],
"summary": "Medtronic reported $36.36 billion in revenue for FY2026, the fiscal year ended April 24, 2026, up 8.4% from a year earlier, with net income attributable to Medtronic of $4.80 billion and diluted earnings per share of $3.73. Operating profit was $6.47 billion, up 8.6%, keeping pace with sales, while net income grew more slowly as a higher effective tax rate absorbed much of the operating gain. Free cash flow was $5.43 billion, up 4.6%, in a year when Medtronic listed its Diabetes business as MiniMed Group and retained a controlling stake in it.",
"qa": [
{
"q": "How much revenue did Medtronic report in FY2026?",
"a": "Medtronic reported $36.36 billion in revenue for FY2026, the fiscal year ended April 24, 2026. That is up 8.4% from $33.54 billion a year earlier, led by the Cardiovascular portfolio, which supplied most of the increase, with the Neuroscience and Medical Surgical portfolios growing more slowly and the smaller Diabetes business growing fastest."
},
{
"q": "How much profit did Medtronic make in FY2026?",
"a": "Net income attributable to Medtronic was $4.80 billion for FY2026, up 3.0% from $4.66 billion a year earlier. Operating profit was $6.47 billion, up 8.6%, and the slower growth in net income reflects a higher effective tax rate rather than weaker operations."
},
{
"q": "What was Medtronic's earnings per share in FY2026?",
"a": "Medtronic reported diluted earnings per share of $3.73 for FY2026, the fiscal year ended April 24, 2026, up 3.3% from $3.61 a year earlier."
},
{
"q": "How much free cash flow did Medtronic generate in FY2026?",
"a": "Medtronic generated $5.43 billion of free cash flow in FY2026, up 4.6% from $5.18 billion a year earlier. Free cash flow here is operating cash flow less additions to property, plant, and equipment, which is Medtronic's own definition."
}
]
},
"company_details": {
"Name": "Medtronic plc",
"Ticker": "MDT",
"CIK": "0001613103",
"Exchange": "NYSE",
"State": "",
"Incorporation": "",
"SIC": "3845",
"Office": "Industrial Applications and Services",
"Industry": "Electromedical & Electrotherapeutic Apparatus"
},
"next_filing": {
"predicted_date": "2026-09-03",
"predicted_type": "10-Q"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "FY",
"tag": "FY26",
"period_end": "2026-04-24",
"form": "10-K",
"accession": "0001628280-26-044354",
"fiscal_year_end": "0424",
"source": "facts"
},
"source_filings": [
{
"role": "annual",
"current": true,
"form": "10-K",
"fiscal_year": 2026,
"fiscal_period": "FY",
"tag": "FY26",
"period_end": "2026-04-24",
"filed": "2026-06-18",
"accession": "0001628280-26-044354",
"url": "https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/0001628280-26-044354-index.htm",
"source": "facts"
}
]
}